Loading stock data…
BioLife Solutions, Inc. (BLFS)
$29.98-0.79 (-2.57%)
Market ClosedLast close Jul 24
BioLife Solutions, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioLife Solutions, Inc. in the Healthcare sector is trading at $29.98 with a market capitalization of $1.3B. Wall Street consensus targets $31.25 (8 analysts), implying a +4.2% move over the next 12 months. The stock is currently near its 52-week high of $32.23, remaining 23.4% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $27.50M↑ | $18.79M↓ | $28.07M↑ | $25.42M↑ | $22.05M |
| Gross Profit | $17.50M↑ | $11.98M↓ | $17.92M↑ | $16.43M↑ | $14.80M |
| Operating Income | $27,000↓ | $1.35M↑ | -$89,000↑ | -$16.64M↓ | -$499,000 |
| Net Income | $1.19M↓ | $11.07M↑ | $621,000↑ | -$15.84M↓ | -$448,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used i...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.33B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.97
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-0.80%
Volume
Today's trading volume
2.60M
Recent News
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout
RGEN's $1.5 billion BioLife acquisition aims to expand its cell therapy capabilities, adding biopreservation products and expected revenue and EPS benefits.
Sector Update: Healthcare Stocks Softer Late Afternoon
Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index down 0.4% and th
Repligen to Buy BioLife Solutions for $1.5 Billion, Expanding Cell Therapy Reach
Repligen (NASDAQ:RGEN) said it has signed a definitive agreement to acquire BioLife Solutions in a transaction valued at approximately $1.5 billion, adding a cell therapy-focused platform that management said will expand Repligen’s exposure to one of the faster-growing areas of bioprocessing. Presi
Top Midday Stories: Trump Threatens Retaliation for Attacks in Strait of Hormuz; AMD to Supply MI450 GPUs to Anthropic
The Dow Jones Industrial Average and the S&P 500 Index were up, while the Nasdaq Composite were down
What Makes BioLife Solutions (BLFS) a Compelling Long-Term Hold?
Prosper Stars & Stripes, a long/short equity fund, recently released its first-quarter 2026 investor letter. A copy of the letter is available to download here. In Q1 2026, the portfolio underperformed with a net return of (-5.6%) compared to the Russell 2000 Index’s +0.9% return and the HFRX Equity Hedge Index’s -1.5% return. Long book performance […]